What Analyst Projections for Key Metrics Reveal About Glaukos (GKOS) Q4 Earnings

Core Insights - Wall Street analysts anticipate Glaukos (GKOS) will report a quarterly loss of $0.43 per share, reflecting a year-over-year increase of 31.8$100.75 million, which represents a 22.3% increase from the same quarter last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating analysts' stability in their forecasts [1] Revenue Estimates - Analysts estimate 'Revenues- Corneal Health' to be $21.53 million, showing a decrease of 1.2$79.53 million, indicating a year-over-year increase of 31.3% [4] - The average prediction for 'Revenues- Glaucoma- United States' stands at $54.32 million, reflecting a significant increase of 40.3$19.10 million, indicating a year-over-year decline of 3% [5] - 'Revenues- International' are projected to be $27.40 million, suggesting a year-over-year increase of 14.3$73.43 million, reflecting a 25.7% increase from the previous year [5] Additional Revenue Insights - Analysts project 'Revenues- Glaucoma- International' to be $25.05 million, indicating a year-over-year increase of 14.6% [6] Stock Performance - Glaukos shares have experienced a decline of 2% over the past month, contrasting with the Zacks S&P 500 composite's increase of 4.7% [7] - With a Zacks Rank of 3 (Hold), Glaukos is expected to closely follow overall market performance in the near term [7]